The U.S. Supreme Court ruled today that the Federal Trade Commission can proceed with its "pay-for-delay" case, which argues that pharmaceutical manufacturers illegally restrict competition by reaching deals with generic drug companies to keep cheaper versions of drugs off the market.
The commission had brought a case which alleged that the decision of Solvay Pharmaceuticals, a subsidiary of Abbott Laboratories, to pay competing drug companies in exchange for an agreement not to market generic versions of a testosterone drug was illegal. ...
Read more: BREAKING: Supreme Court backs FTC in 'pay-for-delay' case | Modern Healthcare http://www.modernhealthcare.com/arti...#ixzz2WUFD1Xf1
Quote from tewdles
and the exclusive for profit model of health care encourages this...
fortunately we are talking here about testosterone and not 5FU, which also has a new, more expensive, non-generic, option.
Big Pharma...bless their greedy little hearts. So good at re-inventing the wheel.
Last edit by OCNRN63 on Jun 17, '13